Cytokine Removal With CVVHD Compared to CVVH

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 13, 2013

Primary Completion Date

November 1, 2015

Study Completion Date

March 1, 2016

Conditions
Cytokine Release SyndromeSepsisAKI
Interventions
PROCEDURE

CVVHD

CVVHD will be used during 72 hours with a prescribed dose of 30 ml/Kg/h Prismasol® 4 as dialysate fluid. Blood flow of 200-250 ml/min, to achieve 12 - 15 L/h will be prescribed. Isovolemic CRRT will be encouraged during this 72 hours if volume overload status is not present. After 72 hours, CVVHD will be continued and dialysate dose (ml/kg/h) will be adjusted to achieve creatinine levels between 80-120 umol/L until patient recovers urine output and / or tolerates intermittent hemodialysis.

PROCEDURE

CVVH

CVVH will be used during 72 hours with a prescribed dose of 30 ml/Kg/h Prismasol® 4 as reposition fluid. Blood flow of 200-250 ml/min, to achieve 12 - 15 L/h will be prescribed adjusting the adequate percentage of prefilter infusion to maintain a theoretical filtration fraction between 18-22%. Isovolemic CRRT will be encouraged if volume overload status is not present. After 72 hours, CVVH will be continued and filtration dose (ml/kg/h) will be adjusted to achieve creatinine levels between 80-120 umol/L until patient recovers urine output and / or tolerates intermittent hemodialysis.

Trial Locations (2)

08907

Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat

Unknown

Hospital de la Santa Creu i Sant Pau, Barcelona

All Listed Sponsors
collaborator

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

OTHER

lead

Hospital Universitari de Bellvitge

OTHER

NCT04048525 - Cytokine Removal With CVVHD Compared to CVVH | Biotech Hunter | Biotech Hunter